TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The purpose of this study is to investigate whether fish oil supplements may reduce the frequency and duration of paroxysmal atrial fibrillation episodes.

Atrial fibrillation is a heart condition which effects a large percentage of the population .

Atrial fibrillation is a condition frequently experienced by people who have had pacemakers inserted .

Certain Pacemakers have sophisticated monitoring features that are able to recognise episodes of atrial fibrillation.

Fish oil supplements may be of benefit to patients with heart problems.Recent evidence suggests that fish oils may be beneficial to patients with rhythm disturbances.

By interrogating pacemakers this study will investigate the effect of fish oil supplements on the frequency and duration of episodes of atrial fibrillation.


Options:
A: Arm Label: Minocycline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Minocycline | Arm Label: Omega-3 fatty acids; Type: ACTIVE_COMPARATOR; Interventions: Drug: Omega-3 fatty acids | Arm Label: Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Minocycline Plus Omega-3 fatty acids; Type: ACTIVE_COMPARATOR; Interventions: Drug: Minocycline Plus Omega-3 fatty acids | Intervention Type: DRUG; Name: Minocycline; Assigned to Arm(s): Minocycline | Intervention Type: DRUG; Name: Omega-3 fatty acids; Assigned to Arm(s): Omega-3 fatty acids | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Minocycline Plus Omega-3 fatty acids; Assigned to Arm(s): Minocycline Plus Omega-3 fatty acids
B: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Dietary counseling, placebo capsules for omega-3 | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: No dietary counseling and omega-3 capsules | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Omega-3 capsules and dietary counseling | Intervention Type: DIETARY_SUPPLEMENT; Name: No dietary counseling and omega-3 capsules; Assigned to Arm(s): 3 | Intervention Type: DIETARY_SUPPLEMENT; Name: Omega-3 capsules and dietary counseling; Assigned to Arm(s): 4 | Intervention Type: DIETARY_SUPPLEMENT; Name: Dietary counseling, placebo capsules for omega-3; Assigned to Arm(s): 2
C: Arm Label: Fish oil; Type: EXPERIMENTAL; Interventions: Drug: Fish oil | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Fish oil; Assigned to Arm(s): Fish oil
D: Intervention Type: DRUG; Name: Eicosapentaenoic acid ethyl ester(EPADEL Capsule 300 TM); Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The purpose of this study is to investigate whether fish oil supplements may reduce the frequency and duration of paroxysmal atrial fibrillation episodes.

Atrial fibrillation is a heart condition which effects a large percentage of the population .

Atrial fibrillation is a condition frequently experienced by people who have had pacemakers inserted .

Certain Pacemakers have sophisticated monitoring features that are able to recognise episodes of atrial fibrillation.

Fish oil supplements may be of benefit to patients with heart problems.Recent evidence suggests that fish oils may be beneficial to patients with rhythm disturbances.

By interrogating pacemakers this study will investigate the effect of fish oil supplements on the frequency and duration of episodes of atrial fibrillation.


Options:
A: Arm Label: Fish oil; Type: EXPERIMENTAL; Interventions: Drug: Fish oil | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Fish oil; Assigned to Arm(s): Fish oil
B: Arm Label: Synbiotic; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Synbiotic | Arm Label: Maltodextrin; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Maltodextrin | Intervention Type: DIETARY_SUPPLEMENT; Name: Synbiotic; Assigned to Arm(s): Synbiotic | Intervention Type: DIETARY_SUPPLEMENT; Name: Maltodextrin; Assigned to Arm(s): Maltodextrin
C: Intervention Type: DRUG; Name: Eicosapentaenoic acid ethyl ester(EPADEL Capsule 300 TM); Assigned to Arm(s): N/A
D: Arm Label: Walnut group; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Walnuts | Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Other: habitual diet | Intervention Type: DIETARY_SUPPLEMENT; Name: Walnuts; Assigned to Arm(s): Walnut group | Intervention Type: OTHER; Name: habitual diet; Assigned to Arm(s): Control group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The purpose of this study is to investigate whether fish oil supplements may reduce the frequency and duration of paroxysmal atrial fibrillation episodes.

Atrial fibrillation is a heart condition which effects a large percentage of the population .

Atrial fibrillation is a condition frequently experienced by people who have had pacemakers inserted .

Certain Pacemakers have sophisticated monitoring features that are able to recognise episodes of atrial fibrillation.

Fish oil supplements may be of benefit to patients with heart problems.Recent evidence suggests that fish oils may be beneficial to patients with rhythm disturbances.

By interrogating pacemakers this study will investigate the effect of fish oil supplements on the frequency and duration of episodes of atrial fibrillation.


Options:
A: Arm Label: Lutein/Zeaxanthin; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Lutein/zeaxanthin | Arm Label: DHA/EPA; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: DHA/EPA | Arm Label: Lutein/Zeaxanthin + DHA/EPA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lutein/zeaxanthin and DHA/EPA | Arm Label: Placebo/Control; Type: PLACEBO_COMPARATOR; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Lutein/zeaxanthin; Assigned to Arm(s): Lutein/Zeaxanthin | Intervention Type: DIETARY_SUPPLEMENT; Name: DHA/EPA; Assigned to Arm(s): DHA/EPA | Intervention Type: DRUG; Name: Lutein/zeaxanthin and DHA/EPA; Assigned to Arm(s): Lutein/Zeaxanthin + DHA/EPA
B: Arm Label: Fish oil; Type: EXPERIMENTAL; Interventions: Drug: Fish oil | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Fish oil; Assigned to Arm(s): Fish oil
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo capsule | Arm Label: EPA-E 1800 mg/day; Type: EXPERIMENTAL; Interventions: Drug: EPA-E 300 mg capsule | Arm Label: EPA-E 2700 mg/day; Type: EXPERIMENTAL; Interventions: Drug: EPA-E 300 mg capsule | Intervention Type: DRUG; Name: Placebo capsule; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: EPA-E 300 mg capsule; Assigned to Arm(s): EPA-E 1800 mg/day | Intervention Type: DRUG; Name: EPA-E 300 mg capsule; Assigned to Arm(s): EPA-E 2700 mg/day
D: Arm Label: Omega 3 fatty acid (fish oil); Type: ACTIVE_COMPARATOR; Interventions: Drug: OMACOR | Arm Label: dummy pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo oral capsule | Intervention Type: DRUG; Name: OMACOR; Assigned to Arm(s): Omega 3 fatty acid (fish oil) | Intervention Type: DRUG; Name: Placebo oral capsule; Assigned to Arm(s): dummy pill

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Double Blind Placebo Controlled Dose Ranging Study of the Efficacy and Safety of SSR149744C 300 or 600 mg for the Conversion of Atrial Fibrillation / Flutter
Brief Summary: Double blind study to assess versus placebo the efficacy of SSR149744C for the conversion of atrial fibrillation/flutter to sinus rhythm at the time of the planned electrical cardioversion.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Radiofrequency ablation | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Conventional treatment | Intervention Type: PROCEDURE; Name: Radiofrequency ablation; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Conventional treatment; Assigned to Arm(s): 2
B: Arm Label: Dronedarone 400mg bid; Type: EXPERIMENTAL; Interventions: Drug: dronedarone (SR33589) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: dronedarone (SR33589); Assigned to Arm(s): Dronedarone 400mg bid | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
C: Arm Label: Dronedarone 400mg bid; Type: EXPERIMENTAL; Interventions: Drug: Dronedarone (SR33589) | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Dronedarone (SR33589); Assigned to Arm(s): Dronedarone 400mg bid | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: CELIVARONE (SSR149744C); Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: VERTOS II. Percutaneous Vertebroplasty Versus Conservative Therapy in Patients With Osteoporotic Vertebral Fractures
Brief Summary: Percutaneous vertebroplasty is a new procedure for treating painful osteoporotic compression fractures of the spine. Five-thousand out of 12.000 patients (16.000 vertebral fractures/year in the Netherlands) present with sudden, severe back pain in the region of the fracture.Until recently, bed rest, analgesia and physical support were the only treatment options. After decades of performing PV, no large RCT with mid-term follow-up has been published.

Design:

This will be a multicenter (6 centers), prospective, randomised, intervention study. Eligible patients will be randomised for percutaneous vertebroplasty or conservative therapy.

Study population:

Age: 50 and older, vertebral fracture, level: thoracic vertebral body 5 (Th 5) or lower, osteopenia (T-score \&lt; -1 SD), back pain for no more than 6 weeks and edema in the vertebrae on MR imaging

Statistical analyses All analyses will be performed on an 'intention to treat' principle. The planned number of subjects will be 200 in total, 100 in each intervention arm.

Economic evaluation:

Cost-effectiveness will be assessed. The costs of the procedure and the medical treatment, and of visits to medical specialists, GP's and physical therapists will be compared.

Time schedule:

The total study will take 36 months

Recruitment of patients (200) has been completed. In May 2009 the 1 year follow-up will be finished.


Options:
A: Arm Label: Vertebroplasty; Type: EXPERIMENTAL; Interventions: Device: Percutaneous vertebroplasty | Arm Label: Control Group; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Sham vertebroplasty | Intervention Type: DEVICE; Name: Percutaneous vertebroplasty; Assigned to Arm(s): Vertebroplasty | Intervention Type: PROCEDURE; Name: Sham vertebroplasty; Assigned to Arm(s): Control Group
B: Arm Label: vertebroplasty; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Kyphoplasty | Arm Label: kyphoplasty; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Kyphoplasty | Intervention Type: PROCEDURE; Name: Kyphoplasty; Assigned to Arm(s): kyphoplasty, vertebroplasty
C: Arm Label: vertebroplasty; Type: EXPERIMENTAL; Interventions: Procedure: percutaneous vertebroplasty | Arm Label: sham procedure; Type: SHAM_COMPARATOR; Interventions: Procedure: sham procedure | Intervention Type: PROCEDURE; Name: percutaneous vertebroplasty; Assigned to Arm(s): vertebroplasty | Intervention Type: PROCEDURE; Name: sham procedure; Assigned to Arm(s): sham procedure
D: Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Vertebroplasty | Intervention Type: PROCEDURE; Name: Vertebroplasty; Assigned to Arm(s): 1

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: VERTOS II. Percutaneous Vertebroplasty Versus Conservative Therapy in Patients With Osteoporotic Vertebral Fractures
Brief Summary: Percutaneous vertebroplasty is a new procedure for treating painful osteoporotic compression fractures of the spine. Five-thousand out of 12.000 patients (16.000 vertebral fractures/year in the Netherlands) present with sudden, severe back pain in the region of the fracture.Until recently, bed rest, analgesia and physical support were the only treatment options. After decades of performing PV, no large RCT with mid-term follow-up has been published.

Design:

This will be a multicenter (6 centers), prospective, randomised, intervention study. Eligible patients will be randomised for percutaneous vertebroplasty or conservative therapy.

Study population:

Age: 50 and older, vertebral fracture, level: thoracic vertebral body 5 (Th 5) or lower, osteopenia (T-score \&lt; -1 SD), back pain for no more than 6 weeks and edema in the vertebrae on MR imaging

Statistical analyses All analyses will be performed on an 'intention to treat' principle. The planned number of subjects will be 200 in total, 100 in each intervention arm.

Economic evaluation:

Cost-effectiveness will be assessed. The costs of the procedure and the medical treatment, and of visits to medical specialists, GP's and physical therapists will be compared.

Time schedule:

The total study will take 36 months

Recruitment of patients (200) has been completed. In May 2009 the 1 year follow-up will be finished.


Options:
A: Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Vertebroplasty | Intervention Type: PROCEDURE; Name: Vertebroplasty; Assigned to Arm(s): 1
B: Arm Label: vertebroplasty; Type: EXPERIMENTAL; Interventions: Procedure: percutaneous vertebroplasty | Arm Label: sham procedure; Type: SHAM_COMPARATOR; Interventions: Procedure: sham procedure | Intervention Type: PROCEDURE; Name: percutaneous vertebroplasty; Assigned to Arm(s): vertebroplasty | Intervention Type: PROCEDURE; Name: sham procedure; Assigned to Arm(s): sham procedure
C: Arm Label: AVAMAX; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Vertebroplasty | Arm Label: Simulated injection procedure; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Vertebroplasty; Assigned to Arm(s): AVAMAX
D: Arm Label: vertebroplasty; Type: ACTIVE_COMPARATOR; Interventions: Procedure: percutaneous injection of cement into the vertebral body | Arm Label: Medical Treatment; Type: ACTIVE_COMPARATOR; Interventions: Other: Medical treatment | Intervention Type: PROCEDURE; Name: percutaneous injection of cement into the vertebral body; Assigned to Arm(s): vertebroplasty | Intervention Type: OTHER; Name: Medical treatment; Assigned to Arm(s): Medical Treatment

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cardiovascular Magnetic Resonance Evaluation of the Effects of Niaspan on Regression of Atherosclerosis and Restoration of Endothelial Function
Brief Summary: AIM 1 will test the hypothesis that elevation of high-density lipoprotein (HDL) through treatment with Niaspan will accelerate the regression of atherosclerotic plaque in patients with established atherosclerosis. The investigators will therefore study patients with atherosclerosis in the aorta and carotid artery. Plaque quantification will be with magnetic resonance imaging (MRI).

AIM 2 will assess the ability of Niaspan to improve endothelial function in patients with coronary artery disease and type II diabetes mellitus, who typically have low high-density lipoprotein cholesterol (HDL-C), and high risk of cardiovascular events.


Options:
A: Intervention Type: DRUG; Name: Niaspan; Assigned to Arm(s): N/A
B: Arm Label: Extended-release niacin; Type: EXPERIMENTAL; Interventions: Drug: extended-release niacin (Niaspan) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: extended-release niacin (Niaspan) | Intervention Type: DRUG; Name: extended-release niacin (Niaspan); Assigned to Arm(s): Extended-release niacin, Placebo
C: Intervention Type: DRUG; Name: Niacin Extended Release and Lovastatin Tablets; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: niacin (+) laropiprant (+) simvastatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Comparator: niacin (+) laropiprant; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Comparator: simvastatin; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: RCT of a Telecommunications System in Sleep Apnea
Brief Summary: This study is investigating the effects of a telecommunications system designed to improve patient adherence with prescribed positive airway pressure (CPAP).


Options:
A: Arm Label: Telemedicine Group; Type: ACTIVE_COMPARATOR; Interventions: Device: Auto CPAP AirSense™ 10(Resmed) | Arm Label: Standard Group; Type: ACTIVE_COMPARATOR; Interventions: Device: Auto CPAP AirSense™ 10(Resmed) | Intervention Type: DEVICE; Name: Auto CPAP AirSense™ 10(Resmed); Assigned to Arm(s): Standard Group, Telemedicine Group
B: Arm Label: standard support; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: coached group; Type: EXPERIMENTAL; Interventions: Behavioral: telephone-based counselling | Intervention Type: BEHAVIORAL; Name: telephone-based counselling; Assigned to Arm(s): coached group
C: Arm Label: TLC-CPAP; Type: EXPERIMENTAL; Interventions: Device: Telecommunications system | Arm Label: TLC-Control; Type: PLACEBO_COMPARATOR; Interventions: Other: TLC-Control | Intervention Type: DEVICE; Name: Telecommunications system; Assigned to Arm(s): TLC-CPAP | Intervention Type: OTHER; Name: TLC-Control; Assigned to Arm(s): TLC-Control
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: Continuous Positive Airway Pressure (CPAP) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard care | Intervention Type: DEVICE; Name: Continuous Positive Airway Pressure (CPAP); Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Standard care; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: RCT of a Telecommunications System in Sleep Apnea
Brief Summary: This study is investigating the effects of a telecommunications system designed to improve patient adherence with prescribed positive airway pressure (CPAP).


Options:
A: Arm Label: TLC-CPAP; Type: EXPERIMENTAL; Interventions: Device: Telecommunications system | Arm Label: TLC-Control; Type: PLACEBO_COMPARATOR; Interventions: Other: TLC-Control | Intervention Type: DEVICE; Name: Telecommunications system; Assigned to Arm(s): TLC-CPAP | Intervention Type: OTHER; Name: TLC-Control; Assigned to Arm(s): TLC-Control
B: Arm Label: Automated Telephone Outreach; Type: EXPERIMENTAL; Interventions: Behavioral: Automated Telephone Outreach with Speech Recognition | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Automated Telephone Outreach with Speech Recognition; Assigned to Arm(s): Automated Telephone Outreach
C: Arm Label: Forecast; Type: EXPERIMENTAL; Interventions: Behavioral: COPD self care advice, Behavioral: Poor weather forecast warning | Arm Label: No Forecast; Type: EXPERIMENTAL; Interventions: Behavioral: COPD self care advice | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: COPD self care advice; Assigned to Arm(s): Forecast, No Forecast | Intervention Type: BEHAVIORAL; Name: Poor weather forecast warning; Assigned to Arm(s): Forecast
D: Arm Label: social cognitive theory; Type: EXPERIMENTAL; Interventions: Behavioral: Social Cognitive Theory | Arm Label: Goal Systems Theory; Type: EXPERIMENTAL; Interventions: Behavioral: goal system theory | Arm Label: Comparison group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Social Cognitive Theory; Assigned to Arm(s): social cognitive theory | Intervention Type: BEHAVIORAL; Name: goal system theory; Assigned to Arm(s): Goal Systems Theory

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Trial to Assess the Use of the Cypher TM Stent in Acute Myocardial Infarction Treated With Balloon Angioplasty
Brief Summary: The main objective of this study is to assess the effectiveness and safety of the CYPHER™ (CYPHER SELECT™) (Sirolimus-eluting) stent in reducing the occurrence of a composite endpoint of target vessel failure (TVF) in subjects treated for acute myocardial infarction as compared to a bare metal stent.


Options:
A: Intervention Type: DRUG; Name: Angiomax (bivalirudin) anticoagulant; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: drug-eluting stent | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: bare-metal stent | Intervention Type: DEVICE; Name: drug-eluting stent; Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: bare-metal stent; Assigned to Arm(s): 2
C: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Device: Drug Eluting Stent (DES) | Arm Label: B; Type: EXPERIMENTAL; Interventions: Device: Drug Eluting Stent (DES) | Arm Label: C; Type: EXPERIMENTAL; Interventions: Device: Drug Eluting Stent (DES) | Intervention Type: DEVICE; Name: Drug Eluting Stent (DES); Assigned to Arm(s): A, B, C
D: Arm Label: Pharmacology Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bivalirudin, Drug: Unfractionated heparin | Arm Label: Stent Arm; Type: ACTIVE_COMPARATOR; Interventions: Device: Bare metal stent, Device: Paclitaxel-eluting stent | Intervention Type: DRUG; Name: Bivalirudin; Assigned to Arm(s): Pharmacology Arm | Intervention Type: DRUG; Name: Unfractionated heparin; Assigned to Arm(s): Pharmacology Arm | Intervention Type: DEVICE; Name: Bare metal stent; Assigned to Arm(s): Stent Arm | Intervention Type: DEVICE; Name: Paclitaxel-eluting stent; Assigned to Arm(s): Stent Arm

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase III, Prospective, Open Label, Multicenter, Randomized Trial of Melphalan, Prednisone and Thalidomide Versus Melphalan and Prednisone as First Line Therapy in Myeloma Patients Aged >65.
Brief Summary: The purpose of this study is to determine whether the association of Thalidomide to Melphalan and Prednisone is effective in the treatment of newly diagnosed elderly multiple myeloma.


Options:
A: Intervention Type: DRUG; Name: bortezomib; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Thalidomide; Assigned to Arm(s): N/A
C: Arm Label: Arm I; Type: EXPERIMENTAL; Interventions: Drug: dexamethasone, Drug: lenalidomide | Arm Label: Arm II; Type: ACTIVE_COMPARATOR; Interventions: Drug: dexamethasone, Other: placebo | Intervention Type: DRUG; Name: dexamethasone; Assigned to Arm(s): Arm I, Arm II | Intervention Type: DRUG; Name: lenalidomide; Assigned to Arm(s): Arm I | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Arm II
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Melphalan/Prednisone/Velcade | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Thalidomide/Prednisone/Velcade | Intervention Type: DRUG; Name: Melphalan/Prednisone/Velcade; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Thalidomide/Prednisone/Velcade; Assigned to Arm(s): B

Answer: B